Although some products like Imfinzi/Imjudo and Soliris underperformed, overall, the company’s performance was bolstered by significant gains in other segments, such as Symbicort and Ultomiris.

AZN beats third-quarter estimates for earnings and sales. It raises its sales and profit outlook for 2024 for the second time ...

AstraZeneca’s earnings were boosted by its oncology, cardiovascular, respiratory and immunology (R&I), and rare disease ...

The company’s comprehensive portfolio includes leading lung cancer medicines and the next wave of innovations, including Tagrisso (osimertinib) and Iressa (gefitinib); Imfinzi (durvalumab) and Imjudo ...

AstraZeneca plans a new investment of $2 billion in the U.S., one of the first major foreign companies to shift spending to ...

One investigation discussed during the call involves sales reps in China allegedly changing genetic testing results to secure reimbursement for Tagrisso.

Total Revenue up 19% to $39,182m, driven by a 19% increase in Product Sales and continued growth in Alliance Revenue from partnered medicines Total Revenue growth from Oncology was 22%, CVRM 21%, R&I ...

Datopotamab deruxtecan new BLA submitted for accelerated approval in the US for patients with previously treated advanced EGFR-mutated non-small cell lung cancer AstraZeneca and Daiichi Sankyo's new ...

The Centers for Disease Control and Prevention typically coordinates between 17 and 36 investigations of foodborne illnesses involving multiple states each week. A report is posted weekly, but ...

In the 630 Battle of al-Qadisiyah, the Arab army emerged victorious and continued its march into Persia, contributing to the spread of Islam beyond West Asia.

Amid fears of an "extremely high level of violent protests," the Brampton Triveni Mandir and Community Centre has cancelled a Life Certificate Event.

Phuket is pulling out all the stops in a monumental bid to raise a whopping 290 million baht. The cause? Building a cutting-edge cancer care centre at Vachira Phuket Hospital. This essential ...